Gene therapy for pituitary tumors: from preclinical models to clinical implementation.
Gene therapy, which entails the use of nucleic acids as drugs, is a new approach to treat disease. Gene therapy has been successfully implemented in several preclinical animal models, including several paradigms of experimental pituitary tumors. In spite of these successes, several critical issues need to be addressed before gene therapy can become a clinical reality for the treatment of pituitary tumors. These include the development of safer and more effective gene delivery vectors, the uncovering of novel therapeutic targets, the development of molecular switches which will allow turning therapeutic transgene expression "on" and "off" as and when it is needed, and the ability to scale up the vector preparations devoid of any putative contaminants. There are still many basic science developments that must take place in order to allow this new therapeutic technology to make its way successfully into the clinical arena to treat pituitary disease. We envisage these developments taking place within the next five years, gene therapy for pituitary tumors will then form part of the armamentarium available to better treat and manage pituitary tumors.
Castro
Maria
M
Gene Therapeutics Research Institute, Cedars-Sinai Medical Center, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 90048-1860, USA. castromg@cshs.org
Goverdhana
Shyam
S
Hu
Jinwei
J
Jovel
Nelson
N
Yuan
Xiangpeng
X
Lowenstein
Pedro
P
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D006564:Herpesviridae / Q000235:genetics; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D010911:Pituitary Neoplasms / Q000235:genetics / Q000628:therapy*